The Sesen Bio (NYSEAMERICAN:SESN) stock has been in focus among investors for quite some time and over the course of the past month, it has managed to garner gains of 75%.
The company is involved in the development of targeted fusion protein therapeutic products that are meant for treating a variety of cancers. Earlier on in the month, the company had announced that it signed a global supply partnership agreement with the Chinese company Qilu Pharmaceutical.
By way of this agreement, the company is going to be supplied with the main drug substance Vicineum. However, that is not all. A technology transfer is also going to take place from Sesen Bio to Qilu Pharmaceutical and currently it is on course to be completed at some point this year.
The technology transfer is an important development since Sesen will get a milestone payment of $2 million once it is completed. At the end of the 1st quarter, the company reported that it had cash and restricted cash to the tune of $110 million, which was far higher than the $55.4 million it had at the end of the previous quarter.
SESN stock is down 1.34% by mid day trading on Tuesday at $2.94.
Moving Averages
| +/- EMA(20) | 2.27 (+29.52%) |
| +/- SMA(50) | 2.16 (+36.11%) |
| +/- SMA(200) | 1.56 (+88.46%) |
Technical Indicators
| Symbol | Value | Result | Symbol | Value | Result |
| ADX | 33.1645 | Sell | ATR14 | 0.2602 | |
| CCI20 | 307.9045 | OverBought | Chaikin Money Flow | 0.0604 | Buy |
| MACD | 0.0950 | Buy | Money Flow Index | 83.9949 | OverBought |
| ROC | 38.6047 | Buy | RSI | 72.2645 | OverBought |
| STOCH (14,3) | 83.5821 | OverBought | STOCH RSI | 1.0000 | OverBought |
| UO | 63.3667 | Buy | Williams %R | -16.4179 | OverBought |
 Stock Soars 75% in a Month: Is The Rally Real?){kind=link}